The U.S. Food and Drug Administration approved the expanded use of Imbruvica, sold by Johnson & Johnson and Pharmacyclics Inc, to treat Waldenström's macroglobulinemia (WM), a rare form of blood cancer for which no specific pharmaceutical therapy exists. WM, a type of non-Hodgkin lymphoma, was discovered more than 70 years ago. It usually worsens slowly over time and causes abnormal blood cells, known as B lymphocytes (B-cells), to grow within the bone marrow, lymph nodes, liver and spleen. The FDA granted Imbruvica breakthrough therapy designation for WM, a status given to drugs seen as important advances in the treatment of serious diseases, but it added a warning that it could cause tumor lysis syndrome (TLS). via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment